206 related articles for article (PubMed ID: 34164830)
41. CD30-Positive Lymphoproliferative Disorders.
Nikolaenko L; Zain J; Rosen ST; Querfeld C
Cancer Treat Res; 2019; 176():249-268. PubMed ID: 30596222
[TBL] [Abstract][Full Text] [Related]
42. Galectin-3 Expression in Primary Cutaneous CD30-Positive Lymphoproliferative Disorders and Transformed Mycosis Fungoides.
Mitteldorf C; Robson A; Tronnier M; Pfaltz MC; Kempf W
Dermatology; 2015; 231(2):164-70. PubMed ID: 26111483
[TBL] [Abstract][Full Text] [Related]
43. Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders.
Abdulla FR; Zhang W; Wu X; Honda K; Qin H; Cho H; Querfeld C; Zain J; Rosen ST; Chan WC; Parekh V; Song JY
JID Innov; 2022 Jan; 2(1):100068. PubMed ID: 34977845
[TBL] [Abstract][Full Text] [Related]
44. Characterization of primary cutaneous CD8+/CD30+ lymphoproliferative disorders.
Martires KJ; Ra S; Abdulla F; Cassarino DS
Am J Dermatopathol; 2015 Nov; 37(11):822-33. PubMed ID: 26485239
[TBL] [Abstract][Full Text] [Related]
45. New developments in non-Hodgkin lymphoid malignancies.
Ganapathi KA; Brown LE; Prakash S; Bhargava P
Pathology; 2021 Apr; 53(3):349-366. PubMed ID: 33685720
[TBL] [Abstract][Full Text] [Related]
46. The morphologic spectrum of primary cutaneous anaplastic large T-cell lymphoma: a histopathologic study on 66 biopsy specimens from 47 patients with report of rare variants.
Massone C; El-Shabrawi-Caelen L; Kerl H; Cerroni L
J Cutan Pathol; 2008 Jan; 35(1):46-53. PubMed ID: 18095994
[TBL] [Abstract][Full Text] [Related]
47. Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma.
Melchers RC; Willemze R; van de Loo M; van Doorn R; Jansen PM; Cleven AHG; Solleveld N; Bekkenk MW; van Kester MS; Diercks GFH; Vermeer MH; Quint KD
Am J Surg Pathol; 2020 Jun; 44(6):776-781. PubMed ID: 32412717
[TBL] [Abstract][Full Text] [Related]
48. CD30+ lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma followed by lymphomatoid papulosis.
Aoki M; Niimi Y; Takezaki S; Azuma A; Seike M; Kawana S
Br J Dermatol; 2001 Jul; 145(1):123-6. PubMed ID: 11453920
[TBL] [Abstract][Full Text] [Related]
49. Histopathological aspects and differential diagnosis of CD8 positive lymphomatoid papulosis.
Marschalkó M; Gyöngyösi N; Noll J; Károlyi Z; Wikonkál N; Hársing J; Kuroli E; Csomor J; Matolcsy A; Sarolta K; Szepesi Á
J Cutan Pathol; 2016 Nov; 43(11):963-973. PubMed ID: 27461449
[TBL] [Abstract][Full Text] [Related]
50. Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin.
Droc C; Cualing HD; Kadin ME
Cancer Control; 2007 Apr; 14(2):124-32. PubMed ID: 17387297
[TBL] [Abstract][Full Text] [Related]
51. No TP63 rearrangements in a selected group of primary cutaneous CD30+ lymphoproliferative disorders with aggressive clinical course.
Schrader AM; Chung YY; Jansen PM; Szuhai K; Bastidas Torres AN; Tensen CP; Willemze R
Blood; 2016 Jul; 128(1):141-3. PubMed ID: 27146432
[No Abstract] [Full Text] [Related]
52. Low-dose radiotherapy for primary cutaneous anaplastic large-cell lymphoma while on low-dose methotrexate.
Cornejo CM; Novoa RA; Krisch RE; Kim EJ
Cutis; 2016 Oct; 98(4):253-256. PubMed ID: 27874877
[TBL] [Abstract][Full Text] [Related]
53. Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma.
Eberle FC; Song JY; Xi L; Raffeld M; Harris NL; Wilson WH; Pittaluga S; Jaffe ES
Am J Surg Pathol; 2012 May; 36(5):716-25. PubMed ID: 22367293
[TBL] [Abstract][Full Text] [Related]
54. Current management of primary cutaneous CD30+ T-cell lymphoproliferative disorders.
Kadin ME
Oncology (Williston Park); 2009 Nov; 23(13):1158-64. PubMed ID: 20043465
[TBL] [Abstract][Full Text] [Related]
55. Evaluation of Associated Lymphomas and Their Risk Factors in Patients with Lymphomatoid Papulosis: A Retrospective Single-Center Study from Turkey.
Baykal C; Kılıç Sayar S; Yazganoğlu KD; Büyükbabani N
Turk J Haematol; 2021 Feb; 38(1):49-56. PubMed ID: 33389922
[TBL] [Abstract][Full Text] [Related]
56. Primary cutaneous anaplastic large cell lymphoma with angioinvasive features and cytotoxic phenotype: a rare lymphoma variant within the spectrum of CD30+ lymphoproliferative disorders.
Kempf W; Kazakov DV; Paredes BE; Laeng HR; Palmedo G; Kutzner H
Dermatology; 2013; 227(4):346-52. PubMed ID: 24246691
[TBL] [Abstract][Full Text] [Related]
57. CD30-positive cutaneous lymphoma: report of four cases with an emphasis on clinicopathological correlations.
Vargas TJ; Jorge SB; Gonzaga YB
An Bras Dermatol; 2017; 92(1):86-91. PubMed ID: 28225962
[TBL] [Abstract][Full Text] [Related]
58. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders.
Benner MF; Jansen PM; Meijer CJ; Willemze R
Br J Dermatol; 2009 Jul; 161(1):121-7. PubMed ID: 19416236
[TBL] [Abstract][Full Text] [Related]
59. Lymphomatoid papulosis associated with Ki-1-positive anaplastic large cell lymphoma. A report of two cases and a review of the literature.
McCarty MJ; Vukelja SJ; Sausville EA; Perry JJ; James WD; Jaffe ES; Weiss RB
Cancer; 1994 Dec; 74(11):3051-8. PubMed ID: 7954268
[TBL] [Abstract][Full Text] [Related]
60. Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement.
Magaki S; Satyadev R; Chen Z; Yung KS; Vinters HV; Kinney MC; Said JW
Brain Tumor Pathol; 2022 Jan; 39(1):25-34. PubMed ID: 34791573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
